文献速递细胞病理与分子病理

细胞病理学中二代测序的一致性与可重复性:改良细胞学分子参考标本的第二次全球环状试验研究

Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.
PubMed 文献 · Cancer Cytopathol · 2019-04-25

该研究通过全球17家实验室对定制细胞离心/细胞甩片参考标准玻片(A-D)进行二代测序(NGS)分析,评估细胞病理学中NGS检测的一致性。结果显示EGFR和KRAS突变检测在10%和5%等位基因频率(AF)下实验室间重现性优秀,但在1% AF时17家实验室中10家(58.82%)漏检至少一个突变;BRAF V600K突变检测和AF定量的符合率较低。结论认为低丰度突变检测在临床中仍具挑战性,可能需要人工审阅测序reads。

要点

  • EGFR和KRAS突变在10%和5% AF下实验室间重现性优秀。
  • 1% AF时17家实验室中10家(58.82%)漏检EGFR或KRAS突变。
  • 低丰度突变检测需人工审阅测序reads,细胞离心参考标准可用于质评。

核心结论

  • 低丰度突变检测在临床中仍具挑战性,可能需要人工审阅测序reads。
  • 细胞离心/细胞甩片格式的基因组参考标准是低AF突变分子检测实验室常规质量评估的有效工具。

研究设计与样本

  • 全球17家实验室分析定制参考标准玻片(A-D),各实验室采用其标准工作流程。
  • 参考标准玻片经优化可在DNA提取前由不同实验室染色,并含有较低细胞数(2×10^5)。
  • 玻片设计涵盖EGFR c.2235_2249del15 p.E746_A750delELREA、EGFR c.2369C>T p.T790M、KRAS c.38G>A p.G13D和BRAF c.1798_1799GT>AA p.V600K突变,处于不同等位基因频率(AF)。

主要发现

  • EGFR和KRAS突变检测显示优秀的实验室间重现性,尤其在玻片A和B(10%和5% AF)上。
  • 在玻片C(1% AF)上,17家实验室中10家(58.82%)未检测到EGFR或KRAS突变。
  • 二次分析重新评估原始数据,突出了首次分析中遗漏的突变(n=10)。
  • BRAF c.1798_1799GT>AA p.V600K在突变检测和AF定量方面显示较低的符合率。

临床怎么用

  • 细胞离心/细胞甩片参考标准可用于低AF突变分子检测实验室的常规质量评估。
  • 对低丰度突变,可能需要人工审阅测序reads以避免漏检。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Artificial genomic reference standards in a cytocentrifuge/cytospin format with well-annotated genomic data are useful for validating next-generation sequencing (NGS) on routine cytopreparations. Here, reference standards were optimized to be stained by different laboratories before DNA extraction and to contain a lower number of cells (2 × 105 ). This was done to better reflect the clinical challenge of working with insufficient cytological material. METHODS: A total of 17 worldwide laboratories analyzed customized reference standard slides (slides A-D). Each laboratory applied its standard workflow. The sample slides were engineered to harbor epidermal growth factor receptor (EGFR) c.2235_2249del15 p.E746_A750delELREA, EGFR c.2369C>T p.T790M, Kirsten rat sarcoma viral oncogene homolog (KRAS) c.38G>A p.G13D, and B-Raf proto-oncogene, serine/threonine kinase (BRAF) c.1798_1799GT>AA p.V600K mutations at various allele frequencies (AFs). RESULTS: EGFR and KRAS mutation detection showed excellent interlaboratory reproducibility, especially on slides A and B (10% and 5% AFs). On slide C (1% AF), either the EGFR mutation or the KRAS mutation was undetected by 10 of the 17 laboratories (58.82%). A reassessment of the raw data in a second-look analysis highlighted the mutations (n = 10) that had been missed in the first-look analysis. BRAF c.1798_1799GT>AA p.V600K showed a lower concordance rate for mutation detection and AF quantification. CONCLUSIONS: The data show that the detection of low-abundance mutations is still clinically challenging and may require a visual inspection of sequencing reads to detect. Genomic reference standards in a cytocentrifuge/cytospin format are a valid tool for regular quality assessment of laboratories performing molecular studies on cytology with low-AF mutations.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Pisapia P, Malapelle U, Roma G, et al. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathol. 2019. PMID: 31021538. doi:10.1002/cncy.22134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。